How many doses are in a Wegovy 0.25mg pen?

Four doses per pen: what the Wegovy 0.25mg licence actually specifies

The Wegovy 0.25mg pen is a pre-filled, single-patient device containing four fixed weekly doses. You inject once a week, on the same day each week, for roughly a month, then return to your prescriber for review before moving up the dose ladder. The number of doses in a Wegovy pen is consistent across the entire range: every strength from 0.25mg to 2.4mg is packaged as a four-dose device, making monthly review the natural rhythm of treatment.

The pen is designed to be straightforward. There is no dial to set, no manual measurement of volume. Each press delivers the same 0.25mg dose, and the device tracks how many injections remain. When the pen is empty after the fourth dose, it is finished. Store it in the fridge between 2°C and 8°C; for storage windows once opened, the Wegovy patient information leaflet is the authoritative reference, not any single online source, including this page.

Injection sites rotate between the abdomen, front of the thigh, and upper arm. The NHS semaglutide medicines page covers injection technique in plain language and is worth bookmarking alongside the leaflet supplied with your pen.

Why 0.25mg exists: the clinical rationale from the STEP trial programme

The STEP 1 trial, published in the New England Journal of Medicine, tested semaglutide at its 2.4mg maintenance dose and found an average weight reduction of around 15% over 68 weeks in adults with obesity. That result comes from reaching and sustaining 2.4mg, the 0.25mg pen contributes none of those headline numbers directly. Its value is preparatory. Beginning at a very low dose substantially reduces the nausea, vomiting and gut discomfort that many people experience when GLP-1 receptor agonists are introduced at full strength.

Clinicians call this an escalation schedule: each four-week pen at each strength gives the gastrointestinal system time to adapt before the next step up. The licensed titration runs 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, then 2.4mg, each step its own four-dose pen, each requiring prescriber review. Wegovy's full dose progression explains what happens at each stage in more detail.

Skipping the 0.25mg pen to get to a therapeutic dose faster is not clinically sanctioned and meaningfully increases the risk of side effects severe enough to force treatment breaks. A question our prescribers hear fairly often is whether the starter pen is necessary if someone has already tolerated semaglutide before, the answer depends on washout period and the prescriber's assessment of the individual case.

What happens after the four doses are used

When your 0.25mg pen is finished you will typically have your next clinical review, which for many patients on a private service like ours happens through a secure follow-up before the next pen is issued. The prescriber checks how you tolerated the starting dose, asks about any side effects, and decides whether you move to the 0.25mg pen for a second month or progress to 0.5mg. That decision belongs to the clinician, not to a protocol running automatically in the background.

If you order by 12pm on a working day and your follow-up is approved, your next pen dispatches the same day and arrives via tracked DPD the next working day, in plain packaging. Timing matters practically, if you are coming to the end of your current pen on a Thursday afternoon, submitting your review request early in the day keeps things moving without a gap.

The cost of each subsequent pen, including the clinical re-review, is covered in a single transparent price. For a clear picture of what that includes, the Wegovy cost context page sets out what private treatment pricing typically covers and what to look for when comparing providers. If you want to understand exactly how each individual strength is packaged and delivered, our guide to Wegovy dose pens covers every device across the titration range, and the doses per Wegovy pen overview covers the same four-dose format applied to every strength, if you want the full picture in one place.

These are prescription-only medicines. Under UK law, a prescriber must assess clinical suitability before any pen is issued, at the 0.25mg stage and at every repeat. Start your free consultation if you would like a same-day clinical review by a GPhC-registered Independent Prescriber.